VYKAT XR

PreclinicalSmall molecule

SSoleno Therapeutics, Inc.

VYKAT XR is one of 15 small molecule programs targeting Prader-Willi syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prader-Willi SyndromeActive, not recruiting

Prader-Willi SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Prader-Willi Syndrome

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

2 2

Intuniv

PPromius Pharma, LLC

Approved

1 3

Topamax

WWim Janssens

Approved

1 4

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

3 5

Pabal

AACADIA Pharmaceuticals Inc.

Phase 3

1 6

Imcivree

Rhythm Pharmaceuticals

Phase 2

2 7

Byetta

AstraZeneca

Preclinical

2 8

BMB-101

BBright Minds Biosciences Pty Ltd

Phase 2

1 9

Arimidex

IIstituto Clinico Humanitas

Preclinical

1 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prader-Willi syndrome1 trial

An Observational Study of VYKAT™ XR (Diazoxide Choline Extended-Release Tablets) in Patients With Prader-Willi Syndrome (PWS)

Enrolling by invitation·SSoleno Therapeutics, Inc.··NCT07450664·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VYKAT XR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VYKAT XR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VYKAT XR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Soleno Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSoleno Therapeutics, Inc.

VYKAT XR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prader-Willi syndrome1 trial

References

Drug Info

Quick Facts

Related News